Risk Assessment of Dyslipidemias, Hyperglycemia, Hyperuricemia, and Hypertension Utilizing Self-Reported Body Silhouettes
Journal of Obesity · 2023
DOI: 10.1155/2023/4991684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obesity, 2023. Verfasst von Ruben Blachman-Braun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA. Hauptthemen laut MEDLINE: Hyperuricemia, Hypertension, Hyperglycemia, Dyslipidemias. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Mexicano del Seguro Social, Universidad Autónoma del Estado de México, Consejo Nacional de Ciencia y Tecnología.
Abstract (Originalsprache)
Objective
Self-reported body silhouette is an anthropometric instrument that has been utilized as a screening tool for underweight, overweight, obesity, and other abnormal anthropometric variables. Herein, we analyzed the risk associated with the self-reported body silhouette in the scope of dyslipidemias, hyperglycemia, hyperuricemia, and hypertension.
Methods
Adult participants of the Health Workers Cohort Study enrolled between March 2004 and April 2006 were included. Then, risk analysis was performed considering dyslipidemias as serum triglycerides, high total cholesterol, high LDL-C, low HDL-C, hyperglycemia, hyperuricemia, and hypertension.
Results
A total of 2,297 males and 5,003 females were analyzed. The median ages of the studied population was 39 (30–49) and 41 (31–50) years for males and females, respectively. Overall, there is a stepwise increase in the risk of presenting dyslipidemias, hyperglycemia, hyperuricemia, and hypertension as the self-reported body silhouette number increases, this tendency was observed in both males and females.
Conclusion
Self-reported body silhouette is a useful risk assessment tool for dyslipidemias, hyperglycemia, hyperuricemia, and hypertension in Mexican adults. Applications of questioners containing this silhouette might be considered a valuable public health instrument due to their low cost, relative simplicity, and absence of specialized equipment, training, or respondent knowledge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.
- Training and Clinical Research Center, Specialty Hospital, Mexican Social Security Institute, National Medical Center XXI, Mexico City, Mexico.
- Teaching Headquarters, ABC Medical Center, Mexico City, Mexico.
- Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, State of Mexico, Mexico.
- Center for Research in Policies, Population and Health, National Autonomous University of Mexico, Mexico City, Mexico.
ORCID-Profile: Ruben Blachman-Braun, Rodolfo Rivas-Ruiz
Förderung
- Instituto Mexicano del Seguro Social
- Universidad Autónoma del Estado de México
- Consejo Nacional de Ciencia y Tecnología
Zitieren
APA
Blachman-Braun, R., Talavera, J. O., Pérez-Rodríguez, M., Roy-García, I., Rivas-Ruiz, R., Huitrón-Bravo, G., & Salmerón, J. (2023). Risk Assessment of Dyslipidemias, Hyperglycemia, Hyperuricemia, and Hypertension Utilizing Self-Reported Body Silhouettes. Journal of Obesity. https://doi.org/10.1155/2023/4991684
Vancouver
Blachman-Braun R, Talavera JO, Pérez-Rodríguez M, Roy-García I, Rivas-Ruiz R, Huitrón-Bravo G, et al. Risk Assessment of Dyslipidemias, Hyperglycemia, Hyperuricemia, and Hypertension Utilizing Self-Reported Body Silhouettes. Journal of Obesity. 2023. doi:10.1155/2023/4991684
BibTeX
@article{BlachmanBraun2023,
author = {Blachman-Braun, Ruben and Talavera, Juan O and Pérez-Rodríguez, Marcela and Roy-García, Ivonne and Rivas-Ruiz, Rodolfo and Huitrón-Bravo, Gerardo and Salmerón, Jorge},
title = {Risk Assessment of Dyslipidemias, Hyperglycemia, Hyperuricemia, and Hypertension Utilizing Self-Reported Body Silhouettes},
journal = {Journal of Obesity},
year = {2023},
doi = {10.1155/2023/4991684}
}
EUVIMED